Compare Amgen, Inc. (AMGN) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs MakeMyTrip Ltd — how do they compare? Amgen, Inc. trades at $356.44 (market cap $196.12B), while MakeMyTrip Ltd trades at $58.77 (market cap $5.56B). The key difference: Amgen, Inc. is far larger — about 35.3× MakeMyTrip Ltd's market cap, and Amgen, Inc. pays a 2.77% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals.
| AMGN | MMYT | |
|---|---|---|
Market Cap | $196.12B | $5.56B |
Sector | Health | Technology |
52-Week High | $388.16 | $103.21 |
52-Week Low | $271.18 | $36.30 |
Enterprise Value | $241.41B | $6.20B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MMYT trades at $58.62, up 1.03% today, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.25 exceeding expectations. Revenue reached $978.34 million in 2025, though net income margin is projected to narrow to 4.96% in 2026. Analyst consensus is strongly positive with 72.73% buy ratings. Recent news highlights temporary travel disruptions but maintains confidence in long-term growth.
The outlook remains favorable given consistent earnings outperformance and robust analyst support, but risks include projected margin compression and rising debt levels. Investors should weigh strong operational cash flow against potential volatility from travel industry headwinds and increasing liabilities in the coming year.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
